Amondys 45
(Casimersen)ApprovedRNA therapy
Sarepta TherapeuticsAmondys 45 is a rna therapy that works as a Exon 45 Skipping ASO.[2] It is being used across 2 indications, with its most advanced program in Approved.[1]
Amondys 45 is one of 69 aso programs targeting Duchenne Muscular Dystrophy. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
68
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
5
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
125 competitors in Duchenne Muscular Dystrophy
#DrugCompanyPhaseTrials
1Cialis
Eli LillyPhase 3
Aldactone
PfizerPhase 3
Rifadin
SanofiPhase 3
Nolvadex
AstraZenecaPhase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Duvyzat
ItalfarmacoPhase 3
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Amondys 45
Sarepta TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Feb 25, 2021
AMONDYS 45
NDA NDA213026
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Casimersen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Exon 45 Skipping ASO[2]
- Modality
- RNA therapy[2]
- Highest Phase
- Approved[1]
- Company